<DOC>
	<DOCNO>NCT01667432</DOCNO>
	<brief_summary>This prospective , multicenter , observational study evaluate on-treatment predictor response patient HBeAg positive HBeAg negative chronic hepatitis B receiving treatment peginterferon alfa-2a ( PEGASYS® ) accordance local labeling summary product characteristic . Data collect patient duration treatment 24 week thereafter .</brief_summary>
	<brief_title>An Observational Study Peginterferon Alfa-2a ( PEGASYS® ) Patients With HBeAg Positive HBeAg Negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient ≥ 18 year age . Hepatitis B envelope antigen ( HBeAg ) positive HBeAg negative hepatitis B without cirrhosis . Elevated alanine aminotransferase ( ALT ) &gt; upper limit normal ( ULN ) ≤ 10 x ULN accord local label . Contraindications peginterferon alfa2a ( PEGASYS® ) detail label . Coinfection hepatitis A , hepatitis C , human immunodeficiency virus ( HIV ) . Concomitant treatment telbivudine . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>